Poland· PL-100462345
Saphnelo
A anifrolumab product containing anifrolumabum, registered in Poland by AstraZeneca AB. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Anifrolumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AG11 (anifrolumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Anifrolumab · ATC L04AG11
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of anifrolumab costs, country by country.
Normalised to the WHO defined daily dose (10.7 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Anifrolumab · price per daily dose (10.7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$42.60
The record
At a glance
URPL (Poland)- Active substance
- Anifrolumabum
- Manufacturer
- AstraZeneca AB
- Country
- Poland (PL)
- ATC code
- L04AG11
- ATC class
- Anifrolumab
- Defined daily dose
- 10.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05000456072700
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Anifrolumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumSaphnelo 300 mgAstraZeneca
- CzechiaSAPHNELOAstraZeneca AB, Södertälje
- FinlandSaphneloAstraZeneca AB
- IrelandSaphnelo 300 mg Concentrate for solution for infusionAstraZeneca AB
- IcelandSaphneloAstraZeneca AB*
- NorwaySaphneloAstraZeneca AB (2)
- SwedenSAPHNELO 300 mg Koncentrat till infusionsvätska, lösningAstraZeneca AB
- SwitzerlandSaphnelo 120 mg/0.8 ml, Injektionslösung in einem FertigpenAstraZeneca AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Saphnelo
- Liechtenstein · Saphnelo
- Norway · Saphnelo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5adafc74-95a5-4542-b650-9169e9d6d869 GET /v1/drugs/5adafc74-95a5-4542-b650-9169e9d6d869?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "300 mg",
"packaging": "05000456072700 ¦ Rpz ¦ EU/1/21/1623/001 ¦ 143975\n1 fiol. 2 ml",
"substance": "Anifrolumabum 300 mg",
"common_name": "Anifrolumabum",
"pl_product_id": "100462345",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about anifrolumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.